1. Home
  2. BILL vs CRSP Comparison

BILL vs CRSP Comparison

Compare BILL & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BILL
  • CRSP
  • Stock Information
  • Founded
  • BILL 2006
  • CRSP 2013
  • Country
  • BILL United States
  • CRSP Switzerland
  • Employees
  • BILL N/A
  • CRSP N/A
  • Industry
  • BILL EDP Services
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BILL Technology
  • CRSP Health Care
  • Exchange
  • BILL Nasdaq
  • CRSP Nasdaq
  • Market Cap
  • BILL 4.7B
  • CRSP 4.9B
  • IPO Year
  • BILL 2019
  • CRSP 2016
  • Fundamental
  • Price
  • BILL $51.08
  • CRSP $56.26
  • Analyst Decision
  • BILL Buy
  • CRSP Buy
  • Analyst Count
  • BILL 22
  • CRSP 16
  • Target Price
  • BILL $61.33
  • CRSP $72.27
  • AVG Volume (30 Days)
  • BILL 5.2M
  • CRSP 1.9M
  • Earning Date
  • BILL 11-06-2025
  • CRSP 11-04-2025
  • Dividend Yield
  • BILL N/A
  • CRSP N/A
  • EPS Growth
  • BILL N/A
  • CRSP N/A
  • EPS
  • BILL N/A
  • CRSP N/A
  • Revenue
  • BILL $1,462,570,000.00
  • CRSP $38,050,000.00
  • Revenue This Year
  • BILL $13.50
  • CRSP $11.17
  • Revenue Next Year
  • BILL $16.99
  • CRSP $296.09
  • P/E Ratio
  • BILL N/A
  • CRSP N/A
  • Revenue Growth
  • BILL 13.36
  • CRSP N/A
  • 52 Week Low
  • BILL $36.55
  • CRSP $30.04
  • 52 Week High
  • BILL $100.19
  • CRSP $71.13
  • Technical
  • Relative Strength Index (RSI)
  • BILL 62.79
  • CRSP 54.66
  • Support Level
  • BILL $45.46
  • CRSP $51.63
  • Resistance Level
  • BILL $54.97
  • CRSP $55.59
  • Average True Range (ATR)
  • BILL 2.28
  • CRSP 2.06
  • MACD
  • BILL 0.83
  • CRSP 0.27
  • Stochastic Oscillator
  • BILL 73.26
  • CRSP 96.36

About BILL BILL Holdings Inc.

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: